Labetalol hydrochloride - Generic Drug Details

What are the generic drug sources for labetalol hydrochloride and what is the scope of patent protection?

Labetalol hydrochloride is the generic ingredient in five branded drugs marketed by Amneal, Apothecon, Baxter Hlthcare Corp, Caplin, Gland Pharma Ltd, Hikma, Hospira, Onesource Specialty, Rising, Schering, Sebela Ireland Ltd, Aiping Pharm Inc, Andas 5 Holding, Appco, Cadila Pharms Ltd, Epic Pharma Llc, Heritage Pharma, Hibrow Hlthcare, Macleods Pharms Ltd, Ph Health, Rubicon Research, Teva, Unichem, Watson Labs, Zydus Pharms, and Alvogen, and is included in thirty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are thirteen drug master file entries for labetalol hydrochloride. Forty-two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for labetalol hydrochloride

US Patents:	0
Tradenames:	5
Applicants:	26
NDAs:	32
Drug Master File Entries:	13
Finished Product Suppliers / Packagers:	42
Raw Ingredient (Bulk) Api Vendors:	93
Clinical Trials:	83
What excipients (inactive ingredients) are in labetalol hydrochloride?	labetalol hydrochloride excipients list
DailyMed Link:	labetalol hydrochloride at DailyMed

Recent Clinical Trials for labetalol hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Cleveland Clinic	NA
Women and Infants Hospital of Rhode Island	PHASE3
Universitas Sumatera Utara	NA

See all labetalol hydrochloride clinical trials

Generic filers with tentative approvals for LABETALOL HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		5MG/ML	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for labetalol hydrochloride

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Medical Subject Heading (MeSH) Categories for labetalol hydrochloride

Adrenergic alpha-1 Receptor Antagonists

Adrenergic beta-Antagonists

Antihypertensive Agents

Sympathomimetics

Anatomical Therapeutic Chemical (ATC) Classes for labetalol hydrochloride

C07AG	Alpha and beta blocking agents
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for labetalol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hibrow Hlthcare	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	207863-003	Feb 4, 2019	AB	RX	No	No
Aiping Pharm Inc	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	075113-001	Aug 4, 1998	AB	RX	No	No
Unichem	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	212719-001	Aug 8, 2022		DISCN	No	No
Macleods Pharms Ltd	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	217949-003	Sep 23, 2025	AB	RX	No	No
Hikma	LABETALOL HYDROCHLORIDE IN DEXTROSE	labetalol hydrochloride	SOLUTION;INTRAVENOUS	213330-001	Nov 9, 2020		RX	Yes	Yes
Heritage Pharma	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	074787-001	Aug 3, 1998	AB	RX	No	No
Appco	LABETALOL HYDROCHLORIDE	labetalol hydrochloride	TABLET;ORAL	209603-004	Oct 18, 2024		RX	No	No

Expired US Patents for labetalol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-002	Aug 1, 1984	4,012,444
Schering	NORMODYNE	labetalol hydrochloride	TABLET;ORAL	018687-004	Aug 1, 1984	4,012,444
Schering	NORMODYNE	labetalol hydrochloride	INJECTABLE;INJECTION	018686-001	Aug 1, 1984	4,012,444
Schering	NORMODYNE	labetalol hydrochloride	TABLET;ORAL	018687-003	Aug 1, 1984	4,012,444
Schering	NORMODYNE	labetalol hydrochloride	TABLET;ORAL	018687-004	Aug 1, 1984	4,066,755
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-004	Aug 1, 1984	4,066,755
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-002	Aug 1, 1984	4,066,755

Market Dynamics and Financial Trajectory for Labetalol Hydrochloride

Last updated: February 19, 2026

Labetalol hydrochloride is a non-selective beta-blocker with alpha-1 blocking activity. It is primarily used to treat hypertension and hypertensive emergencies. The drug’s market landscape is shaped by its patent status, manufacturing availability, clinical demand, and competitive landscape.

Market Overview and Demand Drivers

Labetalol hydrochloride has established itself as a standard therapeutic agent for severe hypertension, especially in hospital settings. It is included in treatment protocols for hypertensive crises and pregnancy-induced hypertension (preeclampsia). The global hypertension management market is projected to grow at a compound annual growth rate (CAGR) of 4-6% over the next five years, supporting steady demand for labetalol formulations [1].

Key demand factors include:

• Rising prevalence of hypertension: Estimated to affect over 1.3 billion adults worldwide (WHO, 2021).
• Pregnancy-related hypertension: Preeclampsia complicates 2-8% of pregnancies globally, ensuring ongoing use in obstetric care [2].
• Hospital protocols: Intravenous use in hypertensive emergencies sustains consistent demand.

Manufacturing and Supply Landscape

Labetalol hydrochloride is currently off patent in many regions, classifying it as a generic drug. Several pharmaceutical companies produce it via chemical synthesis, leading to a competitive landscape characterized by price sensitivity. Key producers include:

• Teva Pharmaceuticals
• Mylan (now part of Viatris)
• Sandoz
• Local generics manufacturers worldwide

The expiration of patents around 2012-2015 in major markets has increased manufacturing capacity and reduced prices, affecting revenue per unit.

Market Segmentation and Geographic Trends

By Formulation

• Injectable: Used in emergency settings; accounts for approximately 35% of market revenue.
• Oral tablets: Predominant form, especially in outpatient hypertensive management; accounts for around 65% of revenue.

By Geography

• North America: Largest market; driven by established healthcare infrastructure and hypertension prevalence.
• Europe: Steady growth owing to aging populations.
• Asia-Pacific: Rapid growth segment; increasing hypertension diagnosis and expanding healthcare access.

Competitive and Regulatory Factors

The widespread availability of generic versions suppresses prices. Regulatory barriers are minimal in most jurisdictions due to established manufacturing processes. Still, as a widely used generic, the potential exists for reducing profit margins.

Patent and Regulatory Outlook

• No active patent protections exist; thus, no exclusive market rights.
• Regulatory approvals maintained for existing formulations without significant hurdles.

Financial Trajectory and Revenue Trends

The global market for labetalol hydrochloride was valued at approximately USD 300 million in 2021. Growth is projected to be roughly 3-4% annually through 2028, driven by the factors outlined above.

Revenue Projections (USD million)

Year	Estimated Market Size	Growth Rate	Notes
2022	312	4%	Continued generic penetration
2023	324	4%	Increased adoption in Asia-Pacific
2024	337	4%	Growing hospital use
2025	350	4%	Steady demand from hypertensive emergencies
2026	364	4%	Aging population drives hypertensive cases
2027	378	4%	Increased use in preeclampsia management
2028	392	4%	Continued market expansion

This revenue trajectory assumes no major shifts in formulation patents or regulatory pathways, and that generic manufacturing remains competitive.

Key Market Risks

• Pricing pressures from generic competition.
• Emerging alternative therapies for hypertension, such as angiotensin receptor blockers.
• Regulatory changes affecting manufacturing or distribution.
• Variations in hypertension prevalence due to health policy interventions.

Conclusion

Labetalol hydrochloride's market outlook remains stable with moderate growth. Its status as a generic agent fosters affordability and widespread use, especially in urgent care and obstetrics. The financial outlook depends on manufacturing efficiencies and competitive pressures, with a steady CAGR of approximately 3-4% through 2028.

Key Takeaways

• Global demand driven primarily by hypertension prevalence and hypertension emergency protocols.
• The market is highly competitive, with no patent protections allowing for price competition.
• Revenue growth is modest but steady, supported by aging populations and expanding healthcare access in emerging markets.
• Pricing pressures and competition from newer antihypertensive agents could influence margins.
• Market stability depends on continued clinical relevance and manufacturer cost efficiencies.

FAQs

1. What are the primary clinical uses of labetalol hydrochloride?

It treats hypertension, hypertensive emergencies, and preeclampsia, administered intravenously in emergencies and orally for outpatient management.

2. How does patent status influence the market for labetalol hydrochloride?

The drug is off patent globally, leading to widespread generic production and price competition, limiting profit margins but ensuring broad access.

3. Which regions are experiencing the fastest growth in labetalol demand?

Asia-Pacific shows the fastest growth, driven by increasing hypertension prevalence and expanding healthcare infrastructure.

4. What are the key factors affecting the future revenue of labetalol hydrochloride?

Patent expiration, generic competition, healthcare policies, and the development of alternative treatments.

5. How might regulatory changes impact the market?

Stricter manufacturing standards or new approval processes could increase costs or reduce supply, impacting availability and pricing.

---

References

[1] WHO. (2021). Hypertension factsheet. https://www.who.int/news-room/fact-sheets/detail/hypertension

[2] American College of Obstetricians and Gynecologists. (2019). Preeclampsia and Hypertensive Disorders. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/11/preeclampsia-and-hypertensive-disorders